Research Article: PPARG expression in colorectal cancer and its association with staging and clinical evolution 1

Date Published: August 17, 2020

Publisher: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia

Author(s): Andre Luiz Prezotto Villa, Rogério Serafim Parra, Marley Ribeiro Feitosa, Hugo Parra de Camargo, Vanessa Foresto Machado, Daniela Pretti da Cunha Tirapelli, José Joaquim Ribeiro da Rocha, Omar Feres.

http://doi.org/10.1590/s0102-865020200070000008

Abstract

To evaluate the gene expression of peroxisome proliferator activated receptors gamma (PPARG) in colorectal tumors and to correlate this data with clinical variables of the patients.

We analyzed the gene expression of PPARG in 50 samples of colorectal tumors using real-time reverse transcription polymerase chain reaction, and 20 adjacent normal tissue samples as control. The results of these quantifications were correlated with the respective patients’ medical records’ clinical information.

PPARG expression was not different in the tumor tissue compared to the control tissue. Patients older than 60 years, histological type with mucinous differentiation, more advanced staging at the time of diagnosis, and patients who evolved with recurrence of the disease or death did not present higher PPARG expression.

Expression of PPARGD was not associated with worse prognosis.

Partial Text

Colorectal cancer (CRC) represents one of the most common cancers in Brazil and in the world, with >200,000 new cases reported each year in United States 1 . Cancer is now widely recognized as a threat to global development. The rates of colorectal cancer are rising among adolescent and young adult patients-defined 2 , 3 . The increase of early-onset CRC incidence suggests more prevention initiatives are urgently warranted for young adults in the near future. Targeted and effective prevention measures are still needed among elderly populations 4 . In addition, recognition of prognostic factors and surgical treatment combined with chemotherapy has contributed to enhancing cure and survival rates in patients with colorectal cancer (CRC) 5 .

Our study showed that PPARG expression was not associated with worse prognosis, not even a better prognosis, as indicated in the literature, despite a tendency of higher levels in more advanced cancers and in patients with recurrence or deceased. Although studies have shown that PPARG is expressed in colon-derived tumors and normal colonic mucosa, the consequence of this on patient outcome is unclear 30 .

PPARG expression was not associated with worse prognosis, and not even a better prognosis, as indicated in the literature, despite a tendency of higher levels in more advanced cancers and in patients with recurrence or deceased.

 

Source:

http://doi.org/10.1590/s0102-865020200070000008

 

Leave a Reply

Your email address will not be published.